BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3090% below fair value
$0.77−0.05 (-6.56%)
Close on Nov 17, 2026Market cap $2.25MP/E –Yield –
BioNexus Gene Lab revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
BioNexus Gene Lab's revenue for the twelve months ending Jun 30, 2026 was $3.13M, down 67.3% year over year. For fiscal 2025 it was $7.42M, down 21.9% from the year before. The highest annual figure on record is $13.36M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.42M | -21.9% |
| FY2024 | Dec 31, 2024 | $9.51M | -2.7% |
| FY2023 | Dec 31, 2023 | $9.77M | -10.6% |
| FY2022 | Dec 31, 2022 | $10.93M | -18.2% |
| FY2021 | Dec 31, 2021 | $13.36M | +17.3% |
| FY2020 | Dec 31, 2020 | $11.39M | +8872.0% |
| FY2019 | Dec 31, 2019 | $126.96K | -40.2% |
| FY2018 | Dec 31, 2018 | $212.33K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $76.16K | -96.6% |
| Q1 FY2026 | Mar 31, 2026 | $22.84K | -98.9% |
| Q4 FY2025 | Dec 31, 2025 | $483.76K | -80.8% |
| Q3 FY2025 | Sep 30, 2025 | $2.54M | -3.3% |
| Q2 FY2025 | Jun 30, 2025 | $2.26M | +14.5% |
| Q1 FY2025 | Mar 31, 2025 | $2.14M | -10.3% |
| Q4 FY2024 | Dec 31, 2024 | $2.52M | +11.0% |
| Q3 FY2024 | Sep 30, 2024 | $2.63M | +3.0% |
| Q2 FY2024 | Jun 30, 2024 | $1.97M | -23.1% |
| Q1 FY2024 | Mar 31, 2024 | $2.38M | +0.2% |
| Q4 FY2023 | Dec 31, 2023 | $2.27M | -20.0% |
| Q3 FY2023 | Sep 30, 2023 | $2.55M | -0.8% |
| Q2 FY2023 | Jun 30, 2023 | $2.57M | +3.3% |
| Q1 FY2023 | Mar 31, 2023 | $2.38M | -21.5% |
| Q4 FY2022 | Dec 31, 2022 | $2.84M | -12.5% |
| Q3 FY2022 | Sep 30, 2022 | $2.58M | -28.0% |
| Q2 FY2022 | Jun 30, 2022 | $2.49M | -19.6% |
| Q1 FY2022 | Mar 31, 2022 | $3.03M | -12.2% |
| Q4 FY2021 | Dec 31, 2021 | $3.25M | -21.3% |
| Q3 FY2021 | Sep 30, 2021 | $3.58M | +15.7% |
| Q2 FY2021 | Jun 30, 2021 | $3.09M | +180.2% |
| Q1 FY2021 | Mar 31, 2021 | $3.45M | +12.3% |
| Q4 FY2020 | Dec 31, 2020 | $4.13M | +7677.5% |
| Q3 FY2020 | Sep 30, 2020 | $3.09M | +12687.0% |
| Q2 FY2020 | Jun 30, 2020 | $1.10M | +4998.2% |
| Q1 FY2020 | Mar 31, 2020 | $3.07M | +10830.0% |
| Q4 FY2019 | Dec 31, 2019 | $53.05K | +463.9% |
| Q3 FY2019 | Sep 30, 2019 | $24.17K | -73.6% |
| Q2 FY2019 | Jun 30, 2019 | $21.65K | -80.6% |
| Q1 FY2019 | Mar 31, 2019 | $28.09K | – |
| Q4 FY2018 | Dec 31, 2018 | $9.41K | – |
| Q3 FY2018 | Sep 30, 2018 | $91.63K | – |
| Q2 FY2018 | Jun 30, 2018 | $111.30K | – |
See a number that looks wrong?